Solventum 2026 Q1: Dental Business Revenue Reaches $354 Million, Up 7.9% Year-over-YearIssuing time:2026-05-06 20:40
DentalGoodNews|May 5, 2026 - Solventum Corporation | NYSE: SOLV released its first-quarter 2026 earnings report. During the reporting period, the company achieved net sales of $2.007 billion, a year-over-year decrease of 3.0%, but organic growth of 2.1%. The company reported sales of approximately $2.0 billion for the quarter, down 3.0% year-over-year, with organic sales growth of 2.1%. Adjusted diluted EPS was $1.48, up 10.6% year-over-year. In terms of business structure, Solventum is currently primarily composed of three segments: Medical Surgical (MedSurg), Dental Solutions, and Health Information Systems (HIS). Among these, the dental business accounted for approximately 18% of the company's Q1 sales.
In the Dental Solutions segment, Solventum returned to growth this quarter, with net sales of related products reaching $354 million, a year-over-year increase of 7.9%, and an organic growth rate of 3.4%. The company stated that the growth in the dental business this quarter was driven by factors such as existing brand strengths, recent product launches, and specialized sales channels. According to previous reports from DENTALGOODNEWS (Leading Dental Industry Media, DGN), Solventum's dental business generated revenue of $343 million in Q4 2025, up 8.6% year-over-year, with organic growth of 5.9%; for the full year 2025, dental business sales reached $1.349 billion, up 4.2% year-over-year, with a full-year operating margin of 25.6%. In terms of cash flow, Solventum reported net operating cash outflow of $189 million for the quarter. Despite short-term cash flow pressure, Solventum maintained its full-year 2026 guidance unchanged, expecting full-year organic sales growth of 2.0% to 3.0%, and adjusted diluted EPS in the range of $6.40 to $6.60, indicating that performance is expected to approach the upper end of the guidance range.
【GOODNEWS】 Content for industry reference only (based on public info & professional judgment); not for decision-making. Readers bear full responsibility for their own judgment and risks.
Copyright © This Platform. Unauthorized reproduction & commercial use prohibited.
Errata, contributions & cooperation: Contact customer service via WeChat:HDSW_001
|
✉️
Subscribe to Our
Newsletter
We curate important stories and exclusive insights, delivered straight to your inbox.
In-depth analysis · Exclusive content · Fast-moving news
|